185 related articles for article (PubMed ID: 29453769)
41. A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.
Mariano VS; Lorenzi AT; Scapulatempo-Neto C; Stein MD; Resende JC; Antoniazzi M; Villa LL; Levi JE; Longatto-Filho A; Fregnani JH
PLoS One; 2016; 11(10):e0164892. PubMed ID: 27764154
[TBL] [Abstract][Full Text] [Related]
42. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
43. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
44. Human telomerase gene and high-risk human papillomavirus infection are related to cervical intraepithelial neoplasia.
Zhao XY; Cui Y; Jiang SF; Liu KJ; Han HQ; Liu XS; Li Y
Asian Pac J Cancer Prev; 2015; 16(2):693-7. PubMed ID: 25684510
[TBL] [Abstract][Full Text] [Related]
45. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
46. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
47. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
49. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
50. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology.
Carozzi F; Cecchini S; Confortini M; Becattini V; Cariaggi MP; Pontenani G; Sani C; Ciatto S
Cancer; 2006 Apr; 108(2):119-23. PubMed ID: 16411180
[TBL] [Abstract][Full Text] [Related]
51. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
52. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
53. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
54. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis.
van der Marel J; van Baars R; Quint WG; Berkhof J; del Pino M; Torné A; Ordi J; Wentzensen N; Schiffman M; van de Sandt MM; Lindeman J; Jenkins D; Helmerhorst TJ; Verheijen RH; ter Harmsel B; Alonso I
BJOG; 2014 Aug; 121(9):1117-26. PubMed ID: 24494663
[TBL] [Abstract][Full Text] [Related]
55. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.
Benevolo M; Ronco G; Mancuso P; Carozzi F; De Marco L; Allia E; Bisanzi S; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Viti J; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Bonvicini L; Venturelli F; Wentzensen N; Giorgi Rossi P;
EBioMedicine; 2024 Jun; 104():105149. PubMed ID: 38759278
[TBL] [Abstract][Full Text] [Related]
56. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
57. The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
Jeronimo J; Bansil P; Valdez M; Kang LN; Zhao FH; Qiao YL; Chen W; Zhang X; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
J Low Genit Tract Dis; 2015 Jul; 19(3):220-3. PubMed ID: 25279978
[TBL] [Abstract][Full Text] [Related]
58. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
[TBL] [Abstract][Full Text] [Related]
59. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.
Bergeron C; Giorgi-Rossi P; Cas F; Schiboni ML; Ghiringhello B; Dalla Palma P; Minucci D; Rosso S; Zorzi M; Naldoni C; Segnan N; Confortini M; Ronco G
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25568167
[TBL] [Abstract][Full Text] [Related]
60. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
